Search

Displaying results 751 - 760 of 3481 in total
  1. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

    Categories: Factor Xa Inhibitors
  2. Drug

    PF-5190457

    go.drugbank.com/drugs/DB14870
    Investigational

    PF-5190457 is under investigation in clinical trial NCT01522807 (A Study Of Three PF-05190457 Formulations In Healthy Volunteers).

  3. Drug

    Imiquimod

    go.drugbank.com/drugs/DB00724
    ApprovedInvestigational

    Imiquimod is an immune response modifier that acts as a toll-like receptor 7 agonist. Imiquimod is commonly used topically to treat warts on the skin of the genital and anal areas. Imiquimod does not cure warts, and new warts may appear ...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesProducts: Aldara P
  4. Drug

    Amorolfine

    go.drugbank.com/drugs/DB09056
    ApprovedWithdrawn

    It is approved for sale over the counter in Australia and the UK (recently re-classified to over the counter status), and is approved for the treatment of toenail fungus by prescription in other countries

    Products: RAZOLE %5 TIRNAK CILASI, 5 ML, RAZOLE %5 TIRNAK CILASI, 2.5 ML
  5. Drug

    Coagulation factor XIa

    go.drugbank.com/drugs/DB15420
    Investigational

    Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).

    Synonyms: Human coagulation factor XICategories: Factor XI
  6. Drug

    Naloxegol

    go.drugbank.com/drugs/DB09049
    ApprovedInvestigational

    The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system

    Synonyms: (5α,6α)-17-Allyl-6-[(20-hydroxy-3,6,9,12,15,18-hexaoxaicos-1-yl)oxy]-4,5-epoxymorphinan-3,14-diolCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  7. Drug

    Erdafitinib

    go.drugbank.com/drugs/DB12147
    ApprovedInvestigational

    tool kit to treat such a prevalent medical condition. … In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  8. Drug

    Adakitug

    go.drugbank.com/drugs/DB05484
    Investigational

    MDX-018, also known as HuMax-Inflam, is a fully human antibody that is directed to IL-8 (interleukin-8) and may have potential application in oncology and inflammation.

    Synonyms: HuMax IL-8, HuMax-IL-8
  9. Drug

    PF-06815345

    go.drugbank.com/drugs/DB14862
    Investigational

    PF-06815345 is under investigation in clinical trial NCT02654899 (Single Dose Study of PF-06815345 in Healthy Subjects).

  10. Drug

    Cyproheptadine

    go.drugbank.com/drugs/DB00434
    ApprovedInvestigational

    Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in ...

    Products: PRAKTEN 2 MG/5 ML ŞURUP, 240 ML, PRAKTEN SURUP, 240 ML